J Korean Med Assoc.  2011 Apr;54(4):386-391. 10.5124/jkma.2011.54.4.386.

Suicide prevention strategies from medical perspective

• Bae SB
• Woo JM

• KMID: 2190421
• DOI: http://doi.org/10.5124/jkma.2011.54.4.386

Abstract

Even though suicide ranks as the fourth cause of death and is causing a significant loss in Korea, it seems that the conventional notion regarding suicide as a feasible way of solving a troublesome life situation hinders early recognition and proper management of suicide. This article reviews suicide prevention strategies recommended based on robust experience and scientific understanding of the characteristics of the suicide problem. In the UK, a suicide prevention strategy was formed at the national level suggesting significant goals to reduce the rate of suicide. In the US, the Institute of Medicine study committee examined the state of the science base, gaps in knowledge, strategies for prevention, and research designs for the study of suicide. This recommendation includes more science-based, coherent and well-coordinated multidisciplinary approaches, and thus suggests important practical recommendations for a suicide prevention strategy of Korea. The author concludes that suicide should be defined as a treatable and even preventable medical condition. Constructing a national network of suicide research, data surveillance, developing tools for suicide prevention including early detection and safety planning, and comprehensive insurance coverage are recommended.

Keyword

Suicide; Depression; Institute of Medicine; Prevention

MeSH Terms

Cause of Death
Depression
Institute of Medicine (U.S.)
Insurance Coverage
Korea
Research Design
Suicide

Figure

• 

  Figure 1 The course of the suicidal process.

Reference

1. World Health Organization. Suicide prevention (SUPRE). 2009. Geneva: World Health Organization.

2. Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, Chen JJ, Mann JJ. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology. 2001. 25:892–903.

3. The Korean Association for Suicide Prevention. The understanding and prevention of suicide. 2007. Seoul: Hakjisa.

4. Lake CR, Baumer J. Academic psychiatry's responsibility for increasing the recognition of mood disorders and risk for suicide in primary care. Curr Opin Psychiatry. 2010. 23:157–166.

5. Injury prevention & control: data & statistics (WISQARS) [Internet]. Centers for Disease Control and Prevention. 2005. cited 2011 Mar 17. Atlanta: Centers for Disease Control and Prevention;Available from: http://www.cdc.gov/injury/wisqars/index.html.

6. Manalai P, Woo JM, Postolache TT. Suicidality and montelukast. Expert Opin Drug Saf. 2009. 8:273–282.

7. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005. 62:165–172.

8. Woo JM, Postolache TT. The impact of work environment on mood disorders and suicide: evidence and implications. Int J Disabil Hum Dev. 2008. 7:185–200.

9. Rihmer Z. Strategies of suicide prevention: focus on health care. J Affect Disord. 1996. 39:83–91.

10. United Nations. Prevention of suicide: guidelines for the formulation and implementation of national strategies. 1996. New York: United Nations.

11. Storbritannien, Secretary of State for Health. Saving lives: our healthier nation. 1999. London: Stationary Office.

12. Great Britain, Department of Health. National suicide preven-tion strategy for England. 2002. London: Department of Health.

13. Goldsmith SK. The Committee on Pathophysiology and Prevention of Adolescent and Adult Suicide. Reducing suicide: a national imperative. 2002. Washington, DC: the National Academy Press.

14. Rotheram-Borus MJ, Piacentini J, Cantwell C, Belin TR, Song J. The 18-month impact of an emergency room intervention for adolescent female suicide attempters. J Consult Clin Psychol. 2000. 68:1081–1093.

15. Stanley B, Brown G, Brent DA, Wells K, Poling K, Curry J, Kennard BD, Wagner A, Cwik MF, Klomek AB, Goldstein T, Vitiello B, Barnett S, Daniel S, Hughes J. Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry. 2009. 48:1005–1013.

16. Brown GK, Ten Have T, Henriques GR, Xie SX, Hollander JE, Beck AT. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA. 2005. 294:563–570.

17. Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry. 2009. 66:1354–1360.

18. Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM Jr, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV. Suicidality and risk of suicide-definition, drug safety concerns, and a necessary target for drug development: a brief report. J Clin Psychiatry. 2010. 71:1040–1046.

19. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007. 164:1035–1043.

20. Wojnar M, Ilgen MA, Wojnar J, McCammon RJ, Valenstein M, Brower KJ. Sleep problems and suicidality in the National Comorbidity Survey Replication. J Psychiatr Res. 2009. 43:526–531.

21. Hawton K, van Heeringen K. Suicide. Lancet. 2009. 373:1372–1381.